Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Earnings Call/Transcript
Jagsonpal Pharmaceuticals scheduled a Q1 FY27 earnings conference call on 2026-07-30 at 14:30 IST to discuss Q1 FY27 financial results; hosted by Go India Advisors. Registration/Dial-in details provided.
Earnings Call/Transcript
Jagsonpal Pharmaceuticals has scheduled an analysts/investors conference call on 2026-07-30 at 14:30 IST to discuss Q1 FY27 financial results; registration details provided in annexure.
Board Meeting
Jagsonpal Pharmaceuticals Ltd informed exchanges its Board will meet on 2026-07-29 to consider and approve unaudited financial results for quarter ended 2026-06-30; trading window closed till 2026-07-31.
Board Meeting
Jagsonpal Pharmaceuticals informed exchanges that its Board will meet on 2026-07-29 to consider and approve unaudited financial results for quarter ended 2026-06-30; trading window closed till 2026-07-31.
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is currently trading at 222.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas. In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance. The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders. Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments. Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹154.90 and a high of ₹301.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jagsonpal Pharmaceuticals Ltd has a market capitalization of approximately 1,463.96. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jagsonpal Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,463.96 Cr, Jagsonpal Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jagsonpal Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 32.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Jagsonpal has signed an agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crore in cash.
The board of Jagsonpal Pharmaceuticals has approved a buyback price of ₹250 per equity share through a tender offer.
The board of Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share, with a total maximum value of ₹40 crore. The buyback will be conducted through a tender offer.
Bearish
2
Neutral
7
Bullish
5
Bearish
14
Neutral
7
Bullish
25
Bearish
12
Neutral
0
Bullish
20
Discovery themes featuring this stock
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas.
In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance.
The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders.
Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments.
Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,464 Cr
Low Risk
32.8
36.7
-1.7
5.3
301.80
154.90
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
899.75 | 1,480 Cr | 45.40 | 5.50 | 0.03 | 11.73 | 15.97 | 5.83 | ||
510.50 | 1,476 Cr | 22.88 | 3.99 | 0.96 | 17.42 | 23.31 | 11.38 | ||
222.20 | 1,464 Cr | 32.80 | 5.30 | 1.83 | 15.60 | 20.59 | 13.60 | ||
31.86 | 1,389 Cr | 63.44 | 15.46 | 0.03 | 24.55 | 31.50 | 18.78 | ||
432.60 | 1,273 Cr | 20.23 | 3.13 | 0.84 | 17.67 | 20.02 | 10.84 | ||
13.10 | 1,231 Cr | 16.17 | 2.97 | 0.00 | 18.42 | 24.46 | 14.32 | ||
494.95 | 1,187 Cr | 27.08 | 4.31 | 0.20 | 15.92 | 21.28 | 13.63 | ||
| Median: 7 Co. | — | 432.60 | 1,389 Cr | 27.08 | 4.31 | 0.20 | 17.42 | 21.28 | 13.60 |
Upcoming Result Date: Jul 28, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
